A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.

Steven G. DuBois,Jill D. Kremer,Bram De Wilde,Chad Jacobsen,Isabelle Aerts,Yael P. Mosse,John M. Maris,Andrew Lithio,Andreas Gosberg,C.L. Banks,Courtney M. Tate,Michele Dowless,Xueqian Gong,Louis Stancato,Katherine M. Bell-McGuinn,Julie R. Park,Andrew D.J. Pearson,Araz Marachelian

A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.

2020

Steven G. DuBois
Jill D. Kremer
Bram De Wilde
Chad Jacobsen
Isabelle Aerts
Yael P. Mosse
John M. Maris
Andrew Lithio
Andreas Gosberg
C.L. Banks
Courtney M. Tate
Michele Dowless
Xueqian Gong
Louis Stancato
Katherine M. Bell-McGuinn
Julie R. Park
Andrew D.J. Pearson
Araz Marachelian

TPS10561Background: Aurora kinase A (AurA) has been implicated in high-risk neuroblastoma, including roles stabilizing and increasing expression of MYCN protein. AurA impacts the function of MYCN i...

Keywords:

Neuroblastoma
phase i study
in patient
Pathology
single agent
relapsed refractory
Medicine
Cancer research
Aurora Kinase A

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations